UBS Group’s Tetraphase Pharmaceuticals TTPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q2
– Sell
-315
Closed -$231K – 9002
2015
Q1
$231K Hold
315
– – ﹤0.01% 4767
2014
Q4
$250K Buy
315
+290
+1,160% +$156K ﹤0.01% 4827
2014
Q3
$10K Buy
+25
New +$6.7K ﹤0.01% 8863

UBS Group's TTPH Position: Q3 2020 in Review

UBS Group sold out of Tetraphase Pharmaceuticals (TTPH) in Q3 2020, closing a stake of 2,925 shares — an estimated $7K sold.

UBS Group first reported a position in TTPH in Q3 2013 and held it in 26 quarters. The position peaked at $1.83M in Q2 2015. 1 fund tracked by Wall St. Rank holds TTPH as of Q3 2020.

  • UBS Group reported no remaining Tetraphase Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • UBS Group sold 2,925 Tetraphase Pharmaceuticals shares in Q3 2020, an estimated $7K.
  • UBS Group first reported a position in Tetraphase Pharmaceuticals in Q3 2013 and held it in 26 quarters.
  • UBS Group's Tetraphase Pharmaceuticals position peaked at $1.83M in Q2 2015.
  • 1 fund tracked by Wall St. Rank held Tetraphase Pharmaceuticals as of Q3 2020.

Based on UBS Group's 13F filing for Q3 2020, filed 12 Nov 2020.